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Abstract Background: Denosumab has recently been shown to be well tolerated, to
increase bone mineral density (BMD) and to significantly reduce the risk of
hip, vertebral and non-vertebral fractures in the FREEDOM (Fracture RE-
duction Evaluation of Denosumab in Osteoporosis every 6Months) trial. It is
becoming increasingly important to evaluate not only the therapeutic value of
a new drug but also the cost effectiveness compared with the most relevant
treatment alternatives.
Objective: The objective of this study was to estimate the cost effectiveness of
denosumab compared with oral bisphosphonates (branded and generic drugs)
in the treatment of post-menopausal osteoporotic women in Belgium.
Methods: Cost effectiveness of 3 years of treatment with denosumab was
compared with branded risedronate and branded and generic alendronate
using an updated version of a previously validated Markov microsimulation
model. The model was populated with relevant cost, adherence and epide-
miological data for Belgium from a payer perspective and the results were
presented as costs per QALY gained (h, year 2009 values). Analyses were per-
formed in populations (aged ‡60 years) in which osteoporosis medications
are currently reimbursed in many European countries, i.e. those with BMD
T-score of -2.5 or less or prevalent vertebral fracture. Patients receiving de-
nosumab were assumed to have a 46% lower risk of discontinuation than those
receiving oral bisphosphonates, and the effect of denosumab after treatment
cessation was assumed to decline linearly to zero over a maximum of 1 year.
Results: Denosumab was cost effective compared with all other therapies,
assuming a willingness to pay of h40 000 per QALY gained. In particular,
denosumab was found to be cost effective compared with branded alen-
dronate and risedronate at a threshold value of h30 000 per QALY and de-
nosumab was dominant (i.e. lower cost and greater effectiveness) compared
with risedronate from the age of 70 years in women with a T-score of -2.5 or
less and no prior fractures. The cost effectiveness of denosumab compared
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with generic alendronate was estimated at h38 514, h22 220 and h27 862 per
QALY for women aged 60, 70 and 80 years, respectively, with T-scores of
-2.5 or less. The equivalent values were h37 167, h19 718 and h19 638 per
QALY for women with prevalent vertebral fractures.
Conclusion: This study suggests, on the basis of currently available data, that
denosumab is a cost-effective strategy compared with oral bisphosphonates
(including generic alendronate) for the treatment of post-menopausal osteo-
porotic women, aged ‡60 years in Belgium. Denosumab therefore appears to
have the potential to become a first-line treatment for post-menopausal
women with osteoporosis. However, further studies would be required to
evaluate the long-term safety and adherence of denosumab in real-world
clinical practice as well as head-to-head effectiveness compared with oral
bisphosphonates.
Key messages
This study suggests, on the basis of currently available data, that denosumab is a cost-effective
strategy compared with branded and generic bisphosphonates for the treatment of post-
menopausal osteoporotic women, aged ‡60 years in Belgium
Denosumab appears to have the potential to become a first-line treatment for post-menopausal
women with osteoporosis
Further studies would be required to evaluate the long-term safety and adherence of denosumab
in real-world clinical practice as well as head-to-head effectiveness compared with oral
bisphosphonates
Background
Osteoporosis has become a major worldwide
health problem, especially in countries with an aging
population. It is a disease characterized by low
bone mass and deterioration of bone tissue that
leads to an increased risk of fracture. One in three
women aged >50 years will experience one or
more fractures attributable to osteoporosis.[1,2] In
Europe alone in 2000, the number of osteoporotic
fractures was estimated at 3.79million, of which
23.5% were hip fractures.[3] Osteoporotic frac-
tures may lead to chronic pain, disability, a reduced
quality of life (QOL) and increased mortality.
Moreover, they place a heavy burden on health-
care resources, with total direct cost estimated
in Europe at h31.7 billion each year (year 2000
value).[4]
Oral bisphosphonates are the first-line treatment
for osteoporosis, with demonstrated efficacy in
reducing the risks of vertebral and non-vertebral
fractures.[5] However, their therapeutic benefits in
clinical practice are often compromised by poor
adherence.[6-8] Approximately 75% of women who
initiate oral bisphosphonates were shown to be
non-adherent within 1 year and 50% discontinued
therapy by this time,[9] resulting in significant
clinical and economic burden.[10] Determinants of
poor adherence include inconvenient regimens,
adverse effects and lack of motivation.[11,12]
Denosumab represents a new therapeutic op-
portunity for the treatment of osteoporosis. The
FREEDOM (Fracture REduction Evaluation of
Denosumab inOsteoporosis every sixMonths) trial
has recently shown subcutaneous administration of
60mg of denosumab every 6 months to be well
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tolerated, to increase bone mineral density (BMD)
and to significantly reduce the risks of vertebral,
non-vertebral and hip fractures in women with
osteoporosis over 3 years.[13] Based on those find-
ings, denosumab was granted marketing authori-
zation from the European Medicines Agency in
May 2010.[14] In addition, patients were shown
to be more satisfied and less bothered with a
6-month injection regimen for osteoporosis than
with a weekly oral tablet.[15] Less frequent dosing
schedules may, in principle, contribute to im-
proved adherence to therapy.[16]
For healthcare decision makers, it would also
be important to know whether denosumab re-
presents ‘good value for money’ compared with
the most relevant alternative treatments. Cost-
effectiveness studies are increasingly utilized in
pricing and reimbursement decisions.[17,18] Decision-
analytic models are necessary to extrapolate beyond
clinical trial data and hence to capture all relevant
costs and consequences. In addition, models allow
the integration of efficacy and safety data from
different clinical trials and thus comparison of
competing treatments, an important feature since
randomized controlled trials (RCTs) rarely com-
pare active therapies.
The objective of this study was, therefore, to
evaluate the cost effectiveness of denosumab com-
pared with oral bisphosphonates (i.e. branded rise-
dronate, branded and generic alendronate) in the
treatment of post-menopausal osteoporotic women
aged ‡60 years in Belgium.
Methods
Analysis
Analyses were performed from the Belgian
healthcare-payer perspective with a lifetime horizon.
The primary outcome measure was the incre-
mental cost-effectiveness ratio (ICER) between
denosumab and comparators, expressed as in-
cremental cost per QALY gained. In the base-
case scenario, annual discount rates of 3.0% and
1.5% were used for costs and QALYs, respec-
tively, as recommended by the Belgian Health-
care Knowledge Centre (KCE) guidelines.[19]
Cost effectiveness was assessed in women
(aged ‡60 years) for whom osteoporosis therapies
are currently reimbursed in several European
countries, i.e. those with BMD T-scores of -2.5
or less, or prevalent vertebral fractures.
Comparators were two oral bisphosphonates
(alendronate and risedronate), the most widely
prescribed drugs for the treatment and prevention
of post-menopausal osteoporosis. Since alendronate
has recently become available as a generic drug, it
was chosen as a reference comparator.
Model Structure
An updated version of a recently published
and validated Markov microsimulation model[20]
was used to assess the cost effectiveness of deno-
sumab. For the purpose of this analysis, a 6-month
cycle lengthwas considered and several data values
were updated, including the long-term cost fol-
lowing hip fracture and mortality rates. The model
was programmed using the software TreeAge Pro
2009 Suite, release 1.0.2 (TreeAge Software Inc.,
Williamston, MA, USA).
Figure 1 provides an overview of the model.
The model health states are ‘no fracture’, ‘death’,
‘hip fracture’, ‘clinical vertebral fracture’, ‘wrist
fracture’, ‘other fracture’ and the corresponding
post-fracture states. A new feature of the model
was the introduction of post-fracture states. This
revision has been required as many parameters
(e.g. fracture disutility, excess mortality) were
only estimated over a 1-year period. The model
followed the patients individually until they died
or reached the age of 105 years. The time horizon
to evaluate the benefit of a particular intervention
should be long enough to capture long-term im-
pact on QOL and costs. Because fractures have a
long-term impact on both, the use of a lifetime
horizon is the most appropriate and has therefore
been recommended for cost-effectiveness anal-
yses of osteoporosis.[21] A 6-month cycle length
was chosen because withdrawals from denosu-
mab can occur every 6 months.
All the women, one at a time, began in the ‘no
fracture’ state and had, every 6 months, a prob-
ability of having a fracture of the hip, clinical
vertebrae, wrist or other site or dying. Women in
a fracture state can stay in the same fracture state
if they re-fracture, change to another fracture
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state, die or change in the next cycle to the post-
fracture state. Because hip fracture is associated
with extra costs in the year following the fracture
that are greater than the hospitalization cost of
any other fracture, patients who have had a hip
fracture were only at risk for another hip fracture
No Fx
Death
Wrist Fx Other Fx
CV FxHip Fx
Post Wrist
Post Hip Post CV
Post Other
Fig. 1. Model structure. Transitions to death and from post-fracture (Fx) states to any Fx states, ‘Death’ and ‘No Fx’ were excluded from the
graph for simplicity. CV = clinical vertebral.
Table I. Incidence of first fracture, cost (h, year 2009 values) and utility data used in the model
Parameter Data
Incidence (annual rate per 1000) of first fracture[1]
Hip fracture 1.57 (60–64 y), 1.88 (65–69 y), 4.49 (70–74 y), 6.69 (75–79 y),
12.13 (80–84 y), 19.65 (85–89 y), 27.29 (90–94 y), 31.72 (95–105 y)
Clinical vertebral fracture 1.93 (60–64 y), 2.10 (65–69 y), 5.16 (70–74 y), 4.83 (75–79 y),
5.70 (80–84 y), 7.60 (85–89 y), 10.55 (90–94 y), 12.26 (95–105 y)
Wrist fracture 7.05 (60–64 y), 6.07 (65–69 y), 8.91 (70–74 y), 6.23 (75–79 y),
6.15 (80–84 y), 6.97 (85–89 y), 9.68 (90–94 y), 11.26 (95–105 y)
Other fracture 3.77 (60–64 y), 5.45 (65–69 y), 7.83 (70–74 y), 9.74 (75–79 y),
13.02 (80–84 y), 21.09 (85–89 y), 29.30 (90–94 y), 34.05 (95–105 y)
Direct fracture cost
Hip, first 6 months[22] 9821 (60 y), 10 183 (65 y), 12 532 (70 y), 13 075 (75 y), 13 798 (80 y),
12 713 (85 y), 12 532 (90–105 y)
Hip, extra cost in the year following the fracture[23] 7870
Hip, yearly long-term costs[22] 1102 (60–69 y), 1272 (70–79 y), 2544 (80–89 y), 3392 (90–99 y), 5088 (100–105 y)
CV, first 6 months[24,25] 2592
Wrist, first 6 months[26] 2302





General population 0.83 (60–69 y), 0.77 (70–79 y), 0.72 (80–105 y)
Hip (first year/subsequent years)a 0.80/0.90
CV (first year/subsequent years)a 0.72/0.93
Wrist (first year/subsequent years)a 0.94/1.00
Other (first year/subsequent years)a 0.91/1.00
a Relative reduction in health utility value, represents the proportional loss of QALY due to the fracture.
BMD = bone mineral density; CV = clinical vertebral.
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or dying in the first cycle following the fracture.
Women in any post-fracture states might have a
new fracture (all fracture types are again possi-
ble), die or move to the ‘no fracture’ state.
Patient history, i.e. prior fractures and residential
status (living either in the community or in a nurs-
ing home), was recorded by tracker variables and
used in calculations of transition probabilities,
costs and utilities to reflect the long-term effects of
fracture and residential status of patients. Using
tracker variables, the restrictive assumptions re-
garding patient movements to health states used in
cohort models are not needed.[20] A patient can
therefore go back to the ‘no fracture’ state, even
after a hip or clinical vertebral fracture. For an
illustration on how the model integrates memory,
please refer to Hiligsmann et al.[20]
Model Inputs
Fracture Incidence
Yearly probabilities of first fracture (at spe-
cific sites) in the general population were taken
from a recently published source[1] (see table I).
Since the incidence of non-hip fractures was not
known in Belgium, this study assumed that the
age-specific ratio of index fracture to hip fracture
in Belgium was the same as found in other coun-
tries. This assumption, frequently used in cost-
effectiveness modelling of osteoporosis, appears
to hold true for West European countries, the US
and Australia.[29]
Fracture risk in the general population needs
to be adjusted to accurately reflect the fracture
risk in the target populations (table II). Low
BMD and prior fractures are associated with in-
creased fracture risk.[30,31] For women with a
BMD T-score of -2.5 or less, the relative risks
(RRs) were calculated using a method previously
described,[32] which estimates the risk of in-
dividuals below the threshold value compared with
the fracture risk in the general population of that
age. The number of standard deviations of BMD
below the age-matched average BMD was de-
rived from the USNational Health and Nutrition
Examination Survey (NHANES) III[33] database,
for which young adult BMD values were not sig-
nificantly different from Belgian estimates (sug-
gesting that values in older adults may also be
similar between the two populations).[34] One
standard deviation decrease in BMD was asso-
ciated with an increase in age-adjusted RR (95%
CI) of 1.8 (1.1, 1.7), 1.4 (1.4, 1.6) and 1.6 (1.4, 1.8)
for clinical vertebral, wrist and other osteoporotic
fracture, respectively.[31] The age-adjusted RR for
hip fracture ranged from 3.1 (2.4, 3.9) at 60 years
to 1.9 (1.8, 2.1) at 85 years.[35] For women with
prevalent vertebral fractures, the RRs were
2.3 (2.0, 2.8), 4.4 (3.6, 5.4), 1.4 (1.2, 1.7) and 1.8
(1.7, 1.9) for hip, clinical vertebral, wrist and other
fracture, respectively.[30] These RRs were reduced
by 10% per decade above the age of 70 years.[36] For
these women, the BMD was assumed to be the
same as the age-matched NHANES population.
However, patients with a prior fracture are likely to
have lower BMD than the general population and
the cost effectiveness of denosumab may therefore
be underestimated in this group.
In the group of women with BMD T-scores of
-2.5 or less and no prior fracture, fracture risk
was also adjusted when a new fracture occurred
during the simulation. An increased risk of sub-
sequent fractures was modelled for women who
had a prior fracture at the same location. These
Table II. Estimates of the relative risk of fracture for women with bone mineral density T-score of -2.5 or less and with prevalent vertebral
fracture
Age range (y) T-score of -2.5 or less Prevalent vertebral fractures
hip vertebral wrist other hip vertebral wrist other
60–69 3.39 2.18 1.61 1.90 2.30 4.40 1.40 1.80
70–79 2.25 1.77 1.43 1.61 2.17 4.06 1.36 1.72
80–89 1.57 1.51 1.30 1.42 2.05 3.75 1.32 1.65
90–99 1.57 1.51 1.30 1.42 1.95 3.48 1.29 1.58
100–105 1.57 1.51 1.30 1.42 1.85 3.23 1.26 1.52
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increased RRs (95% CI) were 4.4 (3.6, 5.4), 2.3
(1.5, 3.7), 3.3 (2.0, 5.3) and 1.9 (1.7, 2.2) for ver-
tebral, hip, wrist and other fractures, respectively.[30]
As the underlying risk of first fracture may con-
tain prior fracture at other sites and a multi-
plicative hypothesis could not be supported at
this time, we conservatively did not model an in-
creased risk of subsequent fractures at sites dif-
ferent from that of the prior fractures. However,
an increased RR of 2.3 (95% CI 2.0, 2.8) is mod-
elled for a hip fracture after a vertebral fracture,
because this effect is largely supported by the lit-
erature.[30] All these increased RRs were increased
by a factor of 1.7 during the year following the
fracture[37] and were reduced by 10% per decade
above the age of 70 years.[36] Further subsequent
fractures of the same type were assumed to have
no additional effect. In the group of women with
prevalent vertebral fractures, fractures during the
simulation process were not associated with an
additional increase in fracture risk.
Mortality Rates
Age-specific mortality rates were derived from
the Belgian National Institute of Statistics.[38]
Excess mortality following a hip fracture was
derived from a Swedish-based population study.[39]
This study gave detailed and conservative esti-
mates in comparison with other studies.[40] The
excess mortality was assumed to be of similar mag-
nitude following a clinical vertebral fracture,[40-43]
and it decreased in subsequent years for both
types of fracture. Because excess mortality may be
attributable to co-morbidities, we conservatively
assumed that only 25% of the excess mortality
following a hip or vertebral fracture could be di-
rectly or indirectly attributable to the fractures
themselves.[42,43]
Therefore, the relative mortality rate in the
year following a hip or clinical vertebral fracture
was estimated at 2.74, 2.09, 1.54, 1.22 and 1.13
for women aged 60, 70, 80, 90 and 100 years, re-
spectively. In subsequent years, the corresponding
values were 1.66, 1.43, 1.16, 1.01 and 1.00, re-
spectively. We also assumed that non-hip, non-
vertebral fractures were not associated with an
increased mortality and in a conservative manner
that a second and further fracture at the same site
will cause no greater mortality excess, except the
increase for the year after they occur.
Utilities
The QALY is an attractive outcome measure in
osteoporosis because therapies have consequences
on both length and quality of life. In the absence
of data specific to Belgium, the utility values used
in the model were derived from a systematic re-
view of the literature.[28] Utility values in the
general population as well as relative reductions
due to fractures in the year following the fracture
and in subsequent years are reported in table I.
Reference values for fracture disutility were gen-
erally derived from a Swedish study, in which
health-related QOL data were collected with the
EQ-5D questionnaire at baseline, 4 months and
12 months after different fractures from a patient
sample of 635 male and female patients.
When a second fracture occurred at the same
site, the disutility applied to the first fracture event
was reduced by 50%.[20] This assumption is sup-
ported by recent studies showing that the number of
fractures is a significant determinant of QOL.[44-46]
Cost Data
The healthcare payer perspective was adopted
for all cost estimates. Only direct medical costs
were considered. All costs were expressed in h,
year 2009 values, using the healthcare product
price index to adjust to year 2009 values.[47]
The costs of hip fracture were retrieved from two
published studies conducted in Belgium: Reginster
et al.[22] estimated the hospitalization cost of hip
fracture based on a retrospective analysis of 2374
patients, while Autier et al.[23] estimated the extra
costs during the year following the hospitalization
from a prospective controlled study including
159 women. Total direct costs in the year following
a hip fracture were therefore estimated to be be-
tween h17 691 and h21 668, according to age.
Wrist fracture cost was estimated at h2302.[26]
The cost of clinical vertebral and other fractures
has never been estimated in Belgium and these
were quantified relative to hip fracture cost. As-
suming that these represent 17% and 25%, re-
spectively, of hip fracture cost,[24,25] they were
estimated, respectively, at h2592 and at h3819
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(unlike Autier et al.,[23] nursing home costs were
not integrated for these proportion factors, so we
reduced hip fracture costs by 50% of their extra
costs before applying the proportion factors).
Hip fractures are also associated with long-
term costs. Hip fracture costs for the second and
subsequent years were based on the proportion of
patients being institutionalized following the frac-
ture, ranging from 5% (for the age range 50–60
years) to 30% (for women aged ‡90 years).[22]
Because women might be institutionalized later in
life, regardless of their hip fracture, an adjustment
was made to only include long-term costs attri-
butable to the fracture itself.[20] Non-hip fractures
were conservatively assumed to be not associated
with long-term costs.
Interventions
In order to assess the cost effectiveness of
osteoporosis medications, data were required on
fracture reduction efficacy (at specific sites), treat-
ment effect duration, the effect of treatment after
stopping therapy, adherence to therapy, adverse
events and intervention cost.[20]
The effect of denosumab on fracture risk was
derived from the 3-year results of the FREEDOM
trial.[13] As compared with placebo, denosumab
reduced the risk of hip fracture by 40% (RR 0.60,
95% CI 0.37, 0.97), the risk of clinical vertebral
fracture by 69% (RR 0.31, 95%CI 0.20, 0.47) and
the risk of other fracture (including wrist frac-
ture) by 20% (RR 0.80, 95% CI 0.67, 0.95) using
the estimated fracture risk reduction for non-ver-
tebral fractures. The effect of oral bisphosphonates
was derived from a recent meta-analysis conducted
for the UK National Institute for Health and
Clinical Excellence appraisal, which included large
RCTs involving post-menopausal women.[48] The
RRs of fracture are reported in table III. The same
efficacy was assumed for generic and branded
alendronate.
Patients in the model received treatment for a
maximum of 3 years, as in the clinical trials. How-
ever, the model simulated a woman’s lifetime in
order to capture all costs and consequences of
fractures experienced during the treatment period.
After stopping therapy, the effect of oral bisphos-
phonates on fracture risk was assumed to decline
linearly to zero for a period (called offset time)
similar to the duration of therapy, in line with
clinical studies[52,53] and previous cost-effectiveness
analyses.[54] For denosumab, we suggested a declin-
Table III. Effectiveness and cost data for denosumab, alendronate and risedronate
Denosumab Alendronate Risedronate
Relative risk of fracture during therapy (95% CI)[13,48]
hip 0.60 (0.37, 0.97) 0.62 (0.40, 0.96) 0.74 (0.59, 0.93)
clinical vertebral 0.31 (0.20, 0.47) 0.56 (0.46, 0.67) 0.64 (0.52, 0.78)
wrist 0.80 (0.67, 0.95) 0.85 (0.67, 1.09) 0.68 (0.43, 1.07)
other fractures 0.80 (0.67, 0.95) 0.82 (0.73, 0.93) 0.80 (0.72, 0.90)




22.9 (6mo), 9.8 (1 y), 4.5 (1.5 y),
3.0 (2 y) and 2.2 (2.5 y)
42.5 (6mo), 18.1 (1 y), 8.3 (1.5 y),
5.6 (2 y) and 4.1 (2.5 y)
42.5 (6mo), 18.1 (1 y), 8.3 (1.5 y),














NA Hip fracture: 1.35 (1.17, 1.56)[49]
All non-hip fractures: 1.17
(1.09, 1.25)[50]
Hip fracture: 1.35 (1.17, 1.56)[49]
All non-hip fractures: 1.17
(1.09, 1.25)[50]
Annual drug cost (h)[51] 414.9 Branded: 283.0
Generic: 159.8
414.9
a Effect of treatment after stopping therapy; duration of the linear decrease in fracture risk reduction.
MPR =medication possession ratio; NA= not applicable; RR = relative risk.
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ing residual effect for a maximum 1-year period, as
previously assumed.[55] This assumption is rather
conservative since recent data have shown that the
treatment benefit achieved (changes in BMD) with
2 years of denosumab therapy was reversed within
2 years of treatment discontinuation.[56]
Adherence
Adherence to osteoporosismedications is amajor
concern[57] and may substantially affect cost-
effectiveness results.[58,59] For modelling purposes,
adherence was divided into ‘compliance’ (i.e. ‘‘the
extent to which a patient acts in accordance with
the prescribed interval and dose of a dosing
regimen’’[60]) and ‘persistence’ (i.e. ‘‘the duration
of time from initiation to discontinuation of
therapy’’[60]). Data on adherence to oral bisphos-
phonates were obtained from the database used
by Rabenda et al.,[49] who conducted a retrospec-
tive cohort analysis including pharmacy records of
post-menopausal women who had received a first
prescription of oral bisphosphonates (daily and
weekly combined) in Belgium between April 2001
and June 2004. Compliance was quantified as the
number of doses taken divided by the number
of doses prescribed – the medication possession
ratio (MPR) – and medication persistence was
captured by the proportion of patients still re-
ceiving medication at different time periods. A
refill gap of 5 weeks was used to assess persis-
tence; i.e. persistence was calculated as the num-
ber of days from the initial prescription to a gap
of more than 5 weeks after completion of the pre-
vious refill. The methodology used to incorporate
compliance and persistence with oral bisphos-
phonates has been published recently.[10,61]
Based on the Belgian observational study,[49]
42.5% ofwomendiscontinued oral bisphosphonates
within 6 months. For these women, no treatment
effect was received[62] and we assigned 3 months
of therapy cost, as previously suggested.[59] An-
other 18.1%, 8.3%, 5.6% and 4.1% of women dis-
continued therapy at 1 year, 1.5 years, 2 years and
2.5 years, respectively. Therefore, only 21.4% of
women received 3 years of treatment. It was as-
sumed that, if patients discontinued therapy, they
received no further treatment and their offset
time was similar to the duration receiving therapy.
Persistent women were considered to be com-
pliant if their MPR was at least 80% in any given
year and poorly compliant, otherwise. An MPR
>80% was commonly used to define high com-
pliance.[8] In the subgroup of persistent women
(including 19 357, 6296 and 1133 women in the
first, second and third year of therapy, respec-
tively), the probabilities of being poorly compliant
(i.e. MPR <80%) were estimated at 23.9%, 4.0%
and 1.2%.[49] These women experience a lower
treatment efficacy. Poor compliance (MPR <80%)
was associated with a 35% increase in hip fracture
rate (RR 1.35, 95% CI 1.17, 1.56).[49] This esti-
mate was derived from the case-control Belgian
study including 901 women who incurred a hip
fracture and were persistent with oral bisphos-
phonates and 4505 randomly selected, matched
controls.[49] Because the Belgian study did not
assess the relationship between compliance and
non-hip fractures, we assumed a conservative[8]
17% increase in other fracture rates (RR 1.17, 95%
CI 1.09, 1.25)[50] for poorly compliant women. The
RRs from the systematic review were applicable
to the population with compliance of ‡80%. For
instance, if alendronate was assumed to reduce the
risk of hip fracture by 38%, then compliant women
would experience a 38% reduction in hip fracture
while poorly compliant women would experience
only a 16.3% (0.62· 1.35= 0.84) reduction in hip
fracture. For poorly compliant women, drug cost
was restricted to the average MPR in this group,
estimated at 74%, 75% and 78% in the first, second
and third year of treatment, respectively.
Persistence with denosumab in real-life settings
is unknown. However, it has been shown that the
mode and schedule of administration may affect
persistence and compliancewith therapy and, in par-
ticular, less frequent regimens have been associated
with better adherence.[16,63] Therefore, persistence
rates for twice-yearly injections of denosumab
would be higher than those previously reported for
daily or weekly bisphosphonates. This has been
recently confirmed by an open-label study of 250
osteoporotic women who were randomized to
either denosumab or branded oral alendronate.[64]
In the first 12 months, significantly more patients
who received denosumab than alendronate were
treatment persistent (risk ratio for discontinua-
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tion 0.54; p= 0.049).[64] Patients receiving denosu-
mab were therefore assumed in our model to have
a 46% lower risk of treatment discontinuation
than patients receiving oral bisphosphonates.
Therefore, 22.9%, 9.8%, 4.5%, 3.0% and 2.2% of
patients treated with denosumab were assumed to
discontinue therapy at 6 months, 1 year, 1.5 years,
2 years and 2.5 years, respectively. Therefore, 57.6%
of patients received 3 years of treatment. In the
case of discontinuation with denosumab after
6 months, fracture efficacy was assumed during
this period given the large gains in BMD previously
reported[65,66] and a declining effect over the
subsequent 6 months. We also assumed, for both
treatments, that if patients discontinued therapy,
they received no further treatment.
Intervention Costs
Drug prices were based on the official listings
of the Belgian Centre for Pharmacotherapeutic
Information as at April 2010.[51] The annual cost
of risedronate and branded alendronate was es-
timated respectively at h414.9 (Actonel, h95.48
for a package of 84 tablets [5mg], once daily) and
at h283.0 (Fosamax, h65.13 for a package of
12 [70mg] tablets, once per week). For generic
alendronate, we selected the mean cost between
the lowest and the highest price of drugs, i.e.
h159.8 per year (generic prices between h35.67
and h37.9 for a package of 12 [70mg] tablets, once
per week). At the time of the analysis, denosumab
was not commercially available in Belgium and for
the purposes of this analysis we assumed the price
of denosumab to be the same as branded rise-
dronate (i.e. h414.9 per year). A higher price was
tested in sensitivity analyses. We also assigned for
both denosumab and bisphosphonate recipients
the cost of two physician visits (h20 per visit) per
year of treatment and the cost of one bone density
measurement (estimated at h47) at years 1 and 3.[27]
Adverse Events
Adverse events associated with osteoporosis
medications, including denosumab, are usually
mild and transient.[5,13] The cost and QOL impact
of adverse events would be minor and they were
therefore not included in the analysis.
Sensitivity Analyses
A series of sensitivity analyses were performed
on the main model inputs and assumptions to
explore the robustness of the model and the de-
gree of impact on the results. One-way sensitivity
analysis was conducted on key model parameters
for a plausible range of values in order to identify
the drivers of the model results and test the im-
pact on model outcome. The probabilistic sensi-
tivity analysis aimed to evaluate and characterize
uncertainty around the model.
To perform this probabilistic analysis, a specific
distribution was attributed to each parameter
around the point estimate used in the base-case
analysis. Log-Normal distributions were assumed
for fracture risk reduction with therapy and for
increased risk related to poor compliance, as
recommended for RR parameters.[17] A Beta dis-
tribution was assumed for utilities based on con-
fidence intervals and Normal distributions, with
an SD assumed to be 15% of the mean, were used
for the fracture cost and fracture incidence vari-
ables given that a standard error was not avail-
able for these parameters. The distributions of
the relative fracture risks associated with a BMD
T-score of -2.5 or less and with prevalent ver-
tebral fracture were respectively assumed to be
log-Normal and Uniform.
First-order Monte Carlo simulations were per-
formed to estimate the cost effectiveness of denosu-
mab. Base-case analysis and one-way sensitivity
analyses were based on ten simulations of 200 000
trials (patients) in each treatment arm (see the
Model Validation section for justifications). Mean
ICER and 95% CI were calculated for each simula-
tion. For probabilistic sensitivity analyses, the model
was run 200 times based on runs of 50000 patients
per treatment arm. Results are presented in the form
of cost-effectiveness acceptability curves that show the
probability of being cost effective as a function of the
threshold willingness to pay (WTP) per QALY.
Results
Model Validation
The model performed well during validation,
producing fracture incidence and mortality rates
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that were similar to the data. Absolute lifetime risks
of hip fracture and of any osteoporotic fracture
were estimated, respectively, at 18.1% and 48.5%
for women aged 60 years, in line with epidemio-
logical data.[1] Furthermore, results were very sim-
ilar to those previously estimated with the first
version of the model, using a 1-year cycle length.[20]
Tests on model parameters and modelling assump-
tions were also consistent with expected conclusions.
To determine the number of simulations, a
varying number of trials (10 000–500 000) were
run ten times in women aged 70 years with BMD
T-scores of -2.5 or less, providing estimates of the
cost effectiveness of denosumab compared with
generic alendronate. The distance between the
upper and lower bounds of the 95%CIs reached a
plateau from 200 000 trials (figure 2). This num-
ber was deemed sufficient to provide stable re-
sults and was therefore selected for the analyses.
Given the large computational burden when con-
ducting probabilistic sensitivity analyses, the num-
ber of trials was restricted to 50000 for this purpose.
Base-Case Analysis
Lifetime costs, QALYs, number of fractures
and the incremental cost effectiveness of deno-
sumab compared with oral bisphosphonates for
osteoporotic women aged 70 years are shown in
table IV. Denosumab was more effective and
generally more costly than alternative treatments.
The cost per QALY gained of denosumab, lower
than h25000 in all scenarios, increased when com-
pared with a generic drug and was the lowest
when compared with risedronate. In women with
a BMD T-score of -2.5 or less, denosumab was
also less costly than risedronate, and therefore is
considered a dominant strategy. There were no
other marked differences between the two target
populations.
Figure 3 shows that the cost effectiveness of
denosumab generally improved with increasing
age. Denosumabwas cost effective, compared with
all other therapies, at an ICER threshold value of
h40 000 per QALY gained over the entire age
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Fig. 2. Model validation: distance between the upper and lower
bounds of the 95% CI of the cost effectiveness of denosumab com-
pared with generic alendronate for a varying number of trials run ten
times (in women aged 70 years with bone mineral density T-score
-2.5 or less).
Table IV. Lifetime costs (h, year 2009 values), QALYs, number of fractures and incremental cost-effectiveness ratio (ICER) of denosumab
compared with oral bisphosphonates in osteoporotic women aged 70 years
Lifetime outcomes (per pt) Denosumab Branded alendronate Generic alendronate Risedronate
Women with BMD T-score of -2.5 or less
Costs 12 561 12 312 12169 12565
QALYs 10.4424 10.4248 10.4248 10.4202
No. of fractures 1.2122 1.2393 1.2393 1.2386
ICERa (95% CI) 14 120 (10 109, 16 765) 22 220 (18 628, 24 780) -209 (-4003, 1681)
Women with prevalent vertebral fracture
Costs 11 563 11 198 11055 11426
QALYs 10.3739 10.3482 10.3482 10.3431
No. of fractures 1.2285 1.2558 1.2558 1.2563
ICER (95% CI) 14 166 (12 251, 16 758) 19 718 (17 940, 22 346) 4456 (2573, 6540)
a h per QALY gained for denosumab vs each oral bisphosphonate.
BMD = bone mineral density; pt =patient.
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found to be cost effective compared with branded
alendronate and risedronate at a threshold value
of h30 000 for a QALY, and denosumab was
dominant compared with risedronate from the age
of 70 years in women with densitometric osteopo-
rosis. The cost effectiveness (95%CI) of denosumab
compared with generic alendronate was esti-
mated at h38 514 (31 664, 45872), h22220 (18 628,
24 780) and h27 862 (22 685, 36 065) per QALY
for women with BMD T-scores of -2.5 or less
aged 60, 70 and 80 years, respectively. The equi-
valent values were h37 167 (32 506, 44 370), h19 718
(17 940, 22 346) and h19 638 (16 936, 24 144)
per QALY for women with prevalent vertebral
fractures.
One-Way Sensitivity Analyses
Results of the one-way sensitivity analyses when
comparing denosumab with generic alendronate
are reported in table V and figure 4. The analyses
presented in table V suggested that the results were
most sensitive to changes in fracture risk and dis-
count rates, and less sensitive to changes in fracture
cost and fracture disutility. So, the ICERs of de-
nosumab increased by 30–41% for higher discount
rates (5% costs, 5% benefits), and by 39–63%when
fracture risk was reduced by 25%. Assuming no
excess mortality following hip and vertebral frac-
ture resulted in higher cost-effectiveness ratios.
Sensitivity analyses on treatment parameters
are presented in figure 4. Results were strongly
influenced by adherence to oral bisphosphonates.
Reducing the probabilities of poor compliance
and of discontinuing generic alendronate by 25%,
the ICER of denosumab was just above h40 000
per QALY gained. The one-way sensitivity analysis
on compliance alone did not have a large impact
on the results. Results were also insensitive to the
presence of monitoring costs and to therapy costs
for women who discontinued oral bisphosphonates
early in the course of treatment. A scenario whereby
a maximum 2-year offset time was assumed for
denosumab had a large impact on the results of
the model. If we assumed a 2-year offset time for
both interventions, the ICER decreased to h12986
(11 191, 15 267). Increasing the cost of denosu-
mab by 15% resulted in higher ICERs, but these
were still below a threshold of h30 000 per QALY.
Even if the cost of generic alendronate was re-
duced by 50%, denosumab remained cost effec-
tive at h26 101 (22 533, 29 638) per QALY.
Probabilistic Sensitivity Analyses
Cost-effectiveness acceptability curves are shown
in figure 5. The curves indicate the probability
that the intervention is cost effective at different
WTP thresholds per 1 QALY. At a threshold of
h40 000 per QALY, denosumab, generic alen-
dronate and risedronate were, respectively, cost






































Fig. 3. Incremental cost-effectiveness ratio of denosumab com-
pared with oral bisphosphonates according to age in women (a) with
bone mineral density T-score of -2.5 or less; and (b) with prevalent
vertebral fracture.
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in women with BMDT-scores of -2.5 or less. The
corresponding probabilities were 89.0%, 11.0% and
0.0% in women with prevalent vertebral fracture.
The intervention with the highest probability
is the one that should be selected for treatment.
Accordingly, in women with BMD T-scores of
-2.5 or less, generic alendronate should be se-
lected if WTP is less than h20 341 per QALY; if it
is higher, denosumab is the strategy of choice. In
women with prevalent vertebral fracture, deno-
sumab is the preferred option for a WTP higher
than h20 333. Risedronate was never a preferred
strategy in our simulations.
Discussion
In this study, a Markov microsimulation model
from a Belgian payer perspective and a lifetime
horizon was used to estimate the cost effective-
ness of denosumab compared with oral bisphos-
phonates. The KCE guidelines do not mention
thresholds for cost effectiveness;[67] however,
the cost per QALY gained of denosumab was
below commonly accepted thresholds of h35 000–
45 000.[54,68,69] Considering these thresholds, the
introduction of denosumab against oral bisphos-
phonates appears to be a cost-effective alternative
for the treatment of post-menopausal osteoporotic
women aged ‡60 years in Belgium. The cost
effectiveness was also robust for most of the pa-
rameters varied in sensitivity analyses. Discount
rates, fracture risk and patient’s adherence to oral
bisphosphonates were found to be particularly
influential when varied within the model.
This study provides the first pharmacoeconomic
evaluation of denosumab compared with alter-
native treatments. We previously showed that de-
nosumab was cost effective for post-menopausal
women with low BMD, but the analysis was re-
stricted to a comparison with no treatment.[55]
Health economic evaluations should ideally com-
pare a new intervention with those interventions
that will likely be replaced. Given that no direct
comparisons are currently available, an indirect
comparison was performed in this study using cur-
rently available clinical data. However, indirect
comparison of efficacy between drugs may be less
robust because of different baseline character-
istics of the populations studied and overlapping
confidence intervals for the effect of treatment.[70]
Our findings would therefore require confirmation,
ideally with head-to-head observational studies
of denosumab comparedwith oral bisphosphonates,
to provide more robust data.
Analyses should also be updated as soon as
new evidence becomes available. Denosumab is
not currently commercially available and has no
defined price. To evaluate the impact of drug price
Table V. One-way sensitivity analyses (conducted on discount rates, fracture risk, cost and disutility and mortality excess) for the cost
effectivenessa of denosumab compared with generic alendronate in osteoporotic women aged 70 years
BMD T-score of -2.5 or less Prevalent vertebral fractures
Base-case analysis 22 220 (18 628, 24 780) 19 718 (17 940, 22 346)
Discount rates 0.00 17145 (13 261, 21 630) 17 399 (15 150, 20 411)
Discount rates 0.03 25850 (21 906, 29 627) 22 307 (20 397, 25 172)
Discount rates 0.05 31359 (25 725, 38 247) 25 681 (23 508, 28 736)
Fracture risk 25% lower 36 125 (30 669, 46 076) 27 406 (21 739, 32 065)
Fracture risk 25% higher 12 374 (9 186, 16 009) 13 614 (11 198, 15 584)
Fracture costs 25% lower 28 380 (24 972, 34 676) 21 134 (18 495, 23 339)
Fracture costs 25% higher 19 609 (16 167, 24 510) 15 899 (11 433, 18 920)
Fracture disutility 25% lower 27 420 (22 634, 34 003) 22 929 (21 058, 26 086)
Fracture disutility 25% higher 19 288 (15 843, 21 601) 15 577 (13 228, 18 295)
No excess mortality after hip and vertebral fractures 34 120 (26 331, 40 436) 28 995 (25 499, 32 421)
No excess mortality after vertebral fracture 24 807 (19 345, 30 298) 25 263 (21 157, 29 122)
a Cost effectiveness is expressed in cost (h, year 2009 values) per QALY gained (95% CI).
BMD = bone mineral density.
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on the results, a higher price was tested, which
could affect cost effectiveness of denosumab.
Additional data are also required on the long-
term safety and efficacy of denosumab, the offset
effect of denosumab after discontinuation and the
persistence with denosumab in real-life settings.
An extension of the FREEDOM trial is currently
ongoing to evaluate the long-term safety and efficacy
of denosumab for the treatment of post-menopausal
osteoporosis. Longitudinal observational studies
will also be useful to estimate the effectiveness of
the drug use in current practice settings and to
document real-world persistence.
Further data on generic alendronate are also
needed. In this study, we assumed the same efficacy
and adherence for branded and generic alendronate,
although there is currently no evidence to support
this assumption. Recent studies have even sug-
gested that persistence and effectiveness with
generic alendronate is poorer than with branded
alendronate.[71,72] Our comparison with generic
alendronate may therefore be conservative for de-
nosumab, by overestimating the ICER (i.e. de-
nosumabmay be more cost effective if persistence
is poorer with generic alendronate), especially
since we adopted a conservative approach for the
effect of treatment after stopping denosumab. In
addition, we have not included adverse effects
with oral bisphosphonates. Although oral
bisphosphonates are generally well tolerated,
they are likely to be associated with upper gas-
trointestinal adverse events,[73] which may re-
quire additional costs.
As with any model, there are potential limita-
tions that should be noted. The most important
are availability of data. Although data used to
construct the model were based on Belgian lit-
erature whenever possible, some data were derived
from other countries. In particular, the incidence
of non-hip fractures and the cost of vertebral and
other fractures were quantified relative to hip
fracture. This proportional assumption appears
to hold true for West European countries, the US
and Australia.[24,25,29] It could also be argued that
hip fractures have been the fracture type con-
sidered to be the key driver of cost effectiveness of
osteoporosis medications,[74] and were estimated
from Belgian published studies. Adherence to
oral bisphosphonates was also derived from a
local study. It would be of considerable value to
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Fig. 4. Tornado diagram for one-way sensitivity analyses (conducted on treatment parameters) on the cost effectiveness of denosumab
compared with generic alendronate (GA) in women aged 70 years with bone mineral density T-score of -2.5 or less. 1 Cost of 4 weeks’ GA for
patients who discontinue therapy within 6 months. 2 Probabilities of being poorly compliant and discontinuation rates in the real-world setting
were reduced by 25%.
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The model used in this study has been pre-
viously validated[20] and has been used in a
number of studies to model the cost effectiveness
of osteoporosis management.[10,27,55,58,61,75,76] The
methodology used to incorporate compliance
and persistence with oral bisphosphonates has
also been recently published.[10,61] Nevertheless,
like all models, several limitations must be taken
into account. Many of these limitations (e.g. ad-
herence data and model assumptions) have been
previously extensively discussed.[10,20] In parti-
cular, assumptions and data on adherence to oral
bisphosphonates, which play a key role in the cost
effectiveness of denosumab, should be acknowl-
edged. First, a refill gap period of 5 weeks was
used to define non-persistence in the Belgian ob-
servational study. However, some patients have
been identified who returned from a temporary
interruption to therapy[77] and it is difficult to
include such patients in modelling because the
effectiveness of oral bisphosphonates used in an
interrupted way is unknown. Second, the use of a
threshold of 80% for good compliance may be
questionable since there is no clinically mean-
ingful definition of good compliance. However,
an MPR of 80% was commonly used to define
high compliance[8] and the use of other thresholds
had limited impact on cost effectiveness in an-
other study.[10] In any event, the cost effectiveness
of denosumab was shown to be moderately sen-
sitive to compliance with oral bisphosphonates.
Third, assigning 3 months of costs for patients
who discontinued within 6 months might not be
realistic, depending on prescribing customs. Oral
bisphosphonates are currently available in Belgium
with a prescription for 4 or 12 weeks. The cost of a
4-week prescription was tested in a sensitivity ana-
lysis, which had limited impact on the results.
In addition, our analysis was performed from a
payer’s perspective rather than a societal one, in
accordance with Belgian methodological guidelines
for pharmacoeconomic evaluations.[19] Taking in-
direct costs such as productivity losses into account
would likely improve the cost effectiveness of de-
nosumab given sensitivity analysis showed that cost
effectiveness improved with higher fracture costs.
The current analyses were conducted only in a
limited number of scenarios in terms of fracture
risk, i.e. in women with BMD T-scores of -2.5 or
less or prevalent vertebral fractures. Our model
probably underestimated the cost effectiveness of
denosumab in the latter group since women with
a prior fracture are likely to have lower BMD
than we conservatively assumed, i.e. that of the
age-matched general population. Additional anal-
yses evaluating the cost effectiveness according
to absolute fracture risk would be valuable. It has
been increasingly suggested that treatment should
be based on absolute fracture risk rather than on
BMD threshold.[5] Recent developments in frac-
ture risk assessment include the FRAX tool, which
estimates the 10-year probability of fracture.[78,79]
FRAX has recently become available in
Belgium.[80] Our simulation model is currently
not able to estimate intervention thresholds.
Finally, the ability of our results to be extrap-
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Fig. 5. Cost-effectiveness acceptability curves in women (a) with
bone mineral density T-score of -2.5 or less; and (b) with prevalent
vertebral fracture. Branded alendronate was not included in the
graph as it was dominated by generic alendronate.
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fracture risk, fracture cost, drug cost and med-
ication adherence differ between countries, and
all have an impact on cost effectiveness. How-
ever, it is likely that countries with similar char-
acteristics to those retained in our analysis will
also show similar cost effectiveness. Belgium is a
country with medium hip fracture risk[81] and a
prior cost-effectiveness analysis of alendronate con-
ducted in nine European countries suggested that
Belgium was in the ‘medium’ group, along with
France and Germany.[54] Sweden, Norway, Den-
mark and the UK had better cost-effectiveness ra-
tios, while Italy and Spain had the worst estimates.
Conclusion
This cost-effectiveness analysis suggests, on
the basis of currently available data, that deno-
sumab is likely to be a cost-effective strategy
compared with oral bisphosphonates (including
generic alendronate) for the treatment of
osteoporosis in post-menopausal women aged
‡60 years in Belgium. Denosumab may therefore
represent a promising treatment option to pre-
vent osteoporotic fractures, especially given the
poor adherence to oral bisphosphonates. The
drug appears to have the potential to become a
first-line treatment for post-menopausal women
with osteoporosis. However, further studies are
required to evaluate the long-term safety of, and
adherence to, denosumab in real-world clinical
practice, as well as head-to-head effectiveness
compared with oral bisphosphonates.
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